Nemonoxacin (TG-873870) malate is a nonfluorinated quinolone antibiotic. Nemonoxacin malate has broad-spectrum activity against Gram-positive, Gram-negative and atypical pathogens. Nemonoxacin malate can inhibit drug-resistant Streptococcus pneumoniae and Methicillin-resistant Staphylococcus aureus. Nemonoxacin malate can be used for the research of community-acquired pneumonia.
Nemonoxacin has antibacterial activity against Chlamydia pneumoniae with MIC90s of 0.06 μg/mL[1].
Nemonoxacin has highly active against community-acquired MRSA (CA-MRSA) (MIC90: 0.5 and 0.06 μg/ml), and exerts limited activity against Ciprofloxacin-resistant MRSA (MIC90: 1 μg/ml), and Vancomycin-intermediate MRSA (MIC90: 2 μg/ml)[2].
References:
[1]. Chotikanatis K, et al. In vitro activity of nemonoxacin, a novel nonfluorinated quinolone antibiotic, against Chlamydia trachomatis and Chlamydia pneumoniae. Antimicrob Agents Chemother. 2014;58(3):1800-1.
[2]. Lai CC, et al. Nemonoxacin (TG-873870) for treatment of community-acquired pneumonia. Expert Rev Anti Infect Ther. 2014 Apr;12(4):401-17.